|
5-fluorouracil (5-FU) Clinical Trials
10 actively recruiting trials across 8 locations
▼ -1 trial since June 2026
Also known as: ADRUCIL®
Pipeline
Phase 1: 3Phase 2: 3Phase 3: 1Phase 1/2: 3
Top Sponsors
- Merck Sharp & Dohme LLC2
- toqa saad mohammed mohammed1
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins1
- Seagen, a wholly owned subsidiary of Pfizer1
- Qilu Pharmaceutical Co., Ltd.1
Indications
- Cancer10
- Gastroesophageal Adenocarcinoma2
- Esophageal Squamous Cell Carcinoma2
- Colorectal Cancer2
- Advanced Gastroesophageal Adenocarcinoma1
Other2 trials
Birmingham, Alabama1 trial
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
UAB Medicine - UAB Hospital
Phase 3
Phoenix, Arizona1 trial
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
Mayo Clinic Hospital
Phase 1
Tucson, Arizona1 trial
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
University of Arizona Cancer Center-University of Arizona Cancer Center ( Site 6927)
Phase 1/2
Encinitas, California1 trial
Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)
California Cancer Associates for Research & Excellence, Inc.
Phase 1
Newark, Delaware1 trial
Hialeah, Florida1 trial
A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States
Bioresearch Partners Holding Hialeah Hospital
Phase 2
Baltimore, Maryland1 trial
NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center
Phase 2
Pittsburgh, Pennsylvania1 trial
Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
UPMC Hillman Cancer Center ( Site 1904)
Phase 1/2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.